期刊文献+

HPV16 L2肽段偶联AP205 VLP的原核表达及免疫原性分析 被引量:1

Prokaryotic Expression and Immunogenicity Analysis of HPV16 L2 Peptide Coupled to AP205VLP
原文传递
导出
摘要 目的:将编码HPV16衣壳蛋白L2的65~71、112~120免疫优势表位连接到RNA噬菌体衣壳蛋白AP205氮端,组装形成病毒样颗粒,通过在大肠杆菌中实现表达及纯化,对其免疫原性进行研究。方法:合成编码AP205衣壳蛋白基因和HPV16 L2的65~71、112~120位氨基酸表位的基因序列,PCR连接并克隆至pET30a(+)原核表达载体,构建重组表达质粒pET30-AP205-HPV16ΔL2,转化大肠杆菌BL21(DH3)感受态细胞,IPTG诱导表达。表达蛋白经凝胶层析纯化及SDS-PAGE、Western blot等理化性质检测,免疫接种ICR小鼠,通过间接ELISA法检测其免疫原性。结果:成功构建重组表达质粒,重组蛋白在大肠杆菌中以可溶性表达,透射电镜观察可见典型病毒样颗粒,该VLP在动物实验中表现出较好的免疫原性。结论:成功将HPV16 L2表位偶联AP205以形成VLP,在大肠杆菌中实现可溶性表达。 Objective: To connect the residues 65 -71 and 112 - 120 of HPV minor capsid protein L2 to the coat protein of RNA bacteriophage AP205. The fusion protein was self-assembled into virus-like-particles (VLPs) after expressing in E. coli, then the protein was purified and the immunogenicity was analyzed. Methods: After being synthesized artificially,the AP205 coat protein gene and HPV16L2 gene were connected by PCR and cloned into vector pET-30a( + ). The constructed plasmid pET30-AP205-HPV16AL2 was transformed to E. coli BL21 (DH3), the recombinant protein was expressed under induction of IPTG and purified by Gel chromatography, then identified through SDS-PAGE and Western blot. The immunogenicity of purified product was measured by indirect ELISA after ICR mouse was immunized. Results: Recombinant plasmid pET30-AP205- HPV16AL2 was constructed correctly and the protein was expressed solubly in E. coli BL21 (DH3). The typical VLPs can be observed through Transmission electron microscopy which Showed good immunogenicity in animal experiments. Conclusion: The HPV16L2 epitope was fused successfully to the N-terminus of AP205 coat protein, and The VLPs was self-assembled in E. coll.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2012年第6期1-6,共6页 China Biotechnology
基金 云南省应用基础研究面上项目(2009ZC186M)
关键词 人乳头瘤状病毒 L2蛋白 AP205 Human papillomavims L2 protein AP205 VLP
  • 相关文献

参考文献13

  • 1Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55 (2) : 74-108.
  • 2de Villiers E M, Fanquet C, Broker T R, et al Classification of papillomaviruses. Virology, 2004,324 : 17-27.
  • 3Harper D M, Franco E L, Wheeler C M,et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet, 2006,367 : 1247-1255.
  • 4Karanam B, Jagu S, Huh W K, et al. Developing vaccines against minor eapsid antigen L2 to prevent papillomavirus infection. Immunology and Cell Biology, 2009,87:287-299.
  • 5Pereira R, Hitzeroth I I, Rybieki E P. Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch Virol, 2009,154 : 187-197.
  • 6Tissot A C, Renhofa R, Sehmitz N, et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS One, 2010,5 : e9809.
  • 7Harper D M, Franco E L, Wheeler C, et al. Efficacy of a bivalent L1 virus - like partical vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet, 2004, 354 (9447): 1757-1765.
  • 8Harper D M. Impact of vaccination with Cervarix^TM on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecologic Oncology,2008,110 : S11-S17.
  • 9徐海燕,辛晓燕,蔡国青.HPV L2肽段宫颈癌疫苗的研究进展[J].中国妇幼健康研究,2008,19(5):489-491. 被引量:3
  • 10Jegerlehner A, Tissot A, Lechner F, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine, 2002,20: 3104-3112.

二级参考文献11

  • 1Munoz N, Bosch F X, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The International perspective[J]. Int J Cancer,2004,111 (2) :278-285.
  • 2Neerja B, Neena L, YAN Ping-bao, et al. A meta-analysis of human papillomavirus type-distribution in women from South Asia: Implications for vaccination [ J ]. Vaccine,2008,2612811-2817.
  • 3Frazer I H. Prevention of cervical cancer through papillomavirus vaccination[ J ]. Nat Rev Immunol,2004 ,4 :46-55.
  • 4Brown C, Gaston K. A quadrivalent vaccine for human papillomavirus [ J]. Drugs Today,2006,42( 11 ) :703-709.
  • 5Hanna E,Bachmann G.HPV vaccination with Gardasil: Abreakt hrough in women's health[ J]. Expert Opin Biol Ther,2006,6( 11 ) : 1223 -1227.
  • 6Mao C. Efficacy of human papillomavirus 216 vaccine to prevent cervical intraep ithelial neop lasia: A randomized controlled trial[ J ]. Obstet Gyneco1,2006,107 : 182-271.
  • 7Suzanne M, Garland M H, Cosette M, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases[ J]. The New England Journal of Medicine,2007,356 : 1928-1943.
  • 8Slupetzky K, Ratish G, Timothy D C, et al. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11[ J ]. Vaccine, 2006,25 ( 2007 ) : 2001-2010.
  • 9Kondo K, Ishii Y, Ochi H, et al. Neutralization of HPV16,18,31, and 58 pseudovirions with antisera niduced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region [ J ]. Virology, 2006,358 ( 2007 ) : 266-272.
  • 10Kim D, Gambhira R, Karanam B, et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine [ J ]. Vaccine, 2008,26:351-360.

共引文献2

同被引文献31

  • 1阿比丹.吐尔汗江,杨润峰,王恬,李莎,栗妍,项涛.人乳头瘤病毒16型E6/E7基因shRNA真核表达载体构建及其对人宫颈癌SiHa细胞增殖及迁移能力的影响[J].肿瘤防治研究,2014,41(5):392-396. 被引量:5
  • 2Heng B, Glenn W K, Ye Y, Tran B, Delprado W, Lutze-Mann L, Whitaker N J, Lawson J S. Human papilloma virus is associated with breast cancer [J]. Brit J Cancer, 2009, 101:1345-1350.
  • 3D'Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine [J]. J Pre- ventive Medicine, 2011, (53) :5-11.
  • 4De M C, Ferlay J, Franceschi S, Vignat J, Bray F, For- man D, Plummer M. Global burden of cancers attribut- able to infections in 2008: a review and synthetic analy- sis [J]. Lancet Oncol, 2012, 13(6) :607-615.
  • 5Conway M J, Meyers C. Replication and assembly of hu- man papillomaviruses [J]. J Dent Res, 2009, 88: 307- 317.
  • 6Johansson C, Schwartz S. Regulation of human papillo mavirus gene expression by splicing and polyadenylation [J]. Nat Rev Mierobiol, 2013, 11:239-251.
  • 7Greco D, Kivi N, Qian K, Leivonen S K, Auvinen P, Auvinen E. Human papillomavirus 16 E5 modulates the expression of host microRNAs [J/OL]. PLoS One, 2011, 6:e21646.
  • 8Wang X, Meyers C, Wang H Khow L T, Zheng Z M. Construction of a full transcription map of human papillomavirus type18 during productive viral infection [J]. J Virol, 2011, 85:8080-8092.
  • 9Florin L, Sapp M, Spoden G A. Host-cell factors in- volved in papillomavirus entry [J]. Med Microbiol Im- munol, 2012, 201:437-448.
  • 10Klingelhutz A J, Roman A. Cellular transformation by human papillomaviruses., lessons learned by comparing high-and low-risk viruses [J]. Virology, 2012, 424: 77-98.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部